Researchers conducting the Leiden Longevity Study, a multi-generational study of Dutch families with exceptional longevity, have identified rare protective genetic variants in 212 groups of long-lived siblings, including a standout mutation that reduces activity of a key inflammatory pathway linked to cellular aging, disease onset, and biological aging acceleration.
The study, published in PMC and presented at the European Society of Human Genetics annual conference, applied whole-genome sequencing and affected sib-pair linkage analysis to identify four chromosomal regions where genetic variations are significantly enriched in long-lived families. Within those regions, researchers prioritized 12 rare protein-altering variants in seven candidate genes.
The most scientifically significant finding involves a missense variant in the CGAS gene — specifically, the variant rs200818241. CGAS encodes the enzyme cyclic GMP-AMP synthase, which is the "sensor" component of the cGAS-STING innate immune pathway. When this sensor detects mislocalized DNA — a hallmark of cellular aging, mitochondrial dysfunction, and oxidative damage — it activates the STING signaling pathway, which in turn drives chronic inflammation, cellular senescence, and immune dysfunction. This is one of the primary molecular mechanisms through which aging generates systemic inflammation.
"Life expectancy has steadily increased in the last two centuries, while healthspan has been lagging behind," the authors wrote in their published paper. "Survival into extreme ages strongly clusters within families which often exhibit a delayed onset of multimorbidity, yet the underlying protective genetic mechanisms are still largely undefined."
What the Mutation Does — and How It Protects Against Aging
The Leiden study team found that the rs200818241 variant in CGAS reduces protein stability in a cell-type-specific manner, effectively making the cGAS sensor less responsive to DNA signals. This dampened sensing attenuates activation of the downstream STING pathway. The downstream effects, validated in both human and mouse cell models, include mitigated inflammation and delayed cellular senescence, the process by which damaged cells stop dividing, accumulate, and release inflammatory signals that harm neighboring tissues.
Cells carrying the variant showed fewer senescence markers and reduced inflammatory signaling compared to cells without it. The protective effect appears to be calibrated rather than complete; the variant doesn't eliminate cGAS-STING signaling (which would impair immune defense), but reduces it to a level that curbs the chronic, low-grade inflammatory activation associated with aging while preserving the pathway's ability to respond to genuine immune threats.
As Fight Aging! summarized the findings, this discovery aligns directly with a growing body of research in comparative biology of aging, showing that cGAS-STING activation is less inflammatory in long-lived species. Researchers have separately engineered mice to express the less inflammatory naked mole-rat version of cGAS and the bat version of STING, with both experiments producing beneficial reductions in age-related inflammation. The human Leiden variant provides the first natural, genetic confirmation in long-lived humans that reduced cGAS-STING activity may contribute to extended, healthier lives.
| Study Design and Key Findings | Detail |
| Study name | Leiden Longevity Study (LLS) — Dutch long-lived families |
| Sibships analyzed | 212 long-lived sibships enriched for ancestral longevity |
| Genomic regions identified | 4 (1q21.1, 6p24.3, 6q14.3, 19p13.3) |
| Candidate genes prioritized | 7 (NUP210L, SLC27A3, CD1A, CGAS, IBTK, RARS2, SH2D3A) |
| Standout variant | rs200818241 in CGAS (missense variant) |
| Pathway affected | cGAS-STING inflammatory signaling pathway |
| Cellular effects | Reduced protein stability; dampened STING activation; delayed senescence |
| Validated in | Human and mouse cell models |
The Leiden Longevity Study was initiated with 421 nonagenarian sibships enrolled between 2002 and 2006, where men had to be older than 89 and women older than 91 to qualify, representing approximately 0.5% of the Dutch population at that time. Their offspring — the second-generation participants in the study — consistently show better health outcomes than age-matched community controls, with studies finding they live approximately 13 healthier years than those without the family longevity background. The CGAS variant contributes to understanding why.
What This Means for Science — and for People Who Don't Have the Variant
The rare nature of the rs200818241 CGAS variant means that the vast majority of people will not carry it. As research summaries including Fight Aging! have noted, rare variants like this one interact with other genetic and lifestyle factors. They rarely operate in isolation.
However, the cGAS-STING pathway finding has two important implications for medicine and for people who want to apply its lessons without the variant. First, the pathway itself becomes a validated drug target. If reducing cGAS-STING activity in a calibrated way — enough to curb chronic inflammation, without eliminating immune defense — is genuinely protective in humans, then pharmaceutical approaches to achieve a similar effect could benefit the broader population. Several biotech companies are already developing cGAS-STING inhibitors for inflammatory and autoimmune conditions; the longevity connection adds a new dimension to those programs.
Second, lifestyle interventions that reduce chronic inflammation, which is the downstream output of overactive cGAS-STING signaling, may simulate some of the protective effects that the rare variant provides genetically. Regular physical activity, Mediterranean-style dietary patterns, adequate and consistent sleep, weight management, smoking cessation, and stress management all reduce systemic inflammatory markers in ways that partially mirror the effect of reduced cGAS-STING pathway activity. These are not as precise as a genetic variant, but they address the same biological process.
Frequently Asked Questions
What is the cGAS-STING pathway, and why does it matter for aging?
The cGAS-STING pathway is an innate immune signaling system. cGAS detects mislocalized DNA, including mitochondrial DNA that leaks into the cell cytoplasm as a result of age-related damage, and activates STING, which drives chronic inflammation, immune dysfunction, and cellular senescence. Overactivation of this pathway is increasingly recognized as a key driver of age-related disease and biological aging acceleration.
What did the Leiden Longevity Study find?
Researchers analyzed 212 sibships of long-lived Dutch families and identified rare protective genetic variants across four chromosomal regions. The most significant finding was a missense variant in CGAS (rs200818241) that reduces cGAS protein stability, dampens STING pathway activation, and delays cellular senescence, effects that are consistent with healthier, slower biological aging.
Does this mean a new anti-aging drug could be developed?
Not immediately, but the finding validates the cGAS-STING pathway as a legitimate drug target for healthy aging. Several pharmaceutical companies are already developing cGAS-STING inhibitors for inflammatory conditions. The Leiden longevity findings add a new biological rationale for exploring whether calibrated pathway inhibition could also promote healthier aging in the broader population.
Do I have this variant? Can I test for it?
The rs200818241 CGAS variant is rare; it was found in only two of the 212 sibships studied. Commercial consumer genetic tests like 23andMe or AncestryDNA may or may not report it, and carrier status does not guarantee any specific health outcome. The variant's protection likely interacts with many other genetic and environmental factors.
What can people do if they don't carry this variant?
The pathway the variant modulates — cGAS-STING-driven chronic inflammation — is also influenced by lifestyle factors. Regular physical activity, Mediterranean-style diet, adequate sleep, and stress management all reduce systemic inflammatory markers in ways that partially address the same biological process. These are not genetic substitutes but operate on the same underlying biology.
